Date: 2016-02-29
Type of information: Nomination
Compound:
Company: Veloxis Pharmaceuticals (Denmark)
Therapeutic area: Transplantation - Renal diseases - Kidney diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 29, 2016, Veloxis Pharmaceuticals announced that Alastair McEwan has been appointed as Chief Operating Officer. Alastair McEwan has been involved in pharmaceutical development and commercialization for over twenty years. He has broad general management, financial and M & A expertise derived from his past roles including President, Global Clinical at Inveresk Research and CFO of Cornerstone Therapeutics during its expansion and integration of EKR and its subsequent sale to Chiesi Farmaceutici. At the same time John Weinberg steps down as Chief Operating Officer.
Financial terms:
Latest news:
